Wrobeln 2017 Artif Cells Nanomed Biotechnol

From Bioblast
Revision as of 15:35, 29 October 2019 by Plangger Mario (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)
Publications in the MiPMap
Wrobeln A, SchlΓΌter KD, Linders J, ZΓ€hres M, Mayer C, Kirsch M, Ferenz KB (2017) Functionality of albumin-derived perfluorocarbon-based artificial oxygen carriers in the Langendorff-heart. Artif Cells Nanomed Biotechnol 45:723-30.

Β» PMID: 28278587 Open Access

Wrobeln A, Schlueter KD, Linders J, Zaehres M, Mayer C, Kirsch M, Ferenz KB (2017) Artif Cells Nanomed Biotechnol

Abstract: The aim of this study was to prove whether albumin-derived perfluorocarbon-based nanoparticles (capsules) can operate as a novel artificial oxygen carrier in a rat Langendorff-heart perfusion model. Hearts perfused with capsules showed increased left ventricular pressure and rate pressure product compared to hearts perfused with pure Krebs-Henseleit (KH)-buffer. The capsules prevented the myocardium from functional fail when in their absence a noxious ischemia was observed. Capsules did not change rheological properties of KH-buffer and could repeatedly reload with oxygen. This albumin-derived perfluorocarbon-based artificial oxygen carrier preserved the function of rat hearts due to the transport of oxygen in a satisfactory manner. Because of these positive results, the functionality of the applied capsules should be verified in living animals. β€’ Keywords: Langendorff-heart, Perfluorocarbon-based artificial oxygen carrier, Albumin, Blood substitutes, Nanocapsules, Perfluorodecalin β€’ Bioblast editor: Plangger M


Labels: MiParea: mt-Medicine, Pharmacology;toxicology 





HRR: Oxygraph-2k 

Labels, 2019-10 

Cookies help us deliver our services. By using our services, you agree to our use of cookies.